EUVIMEDEUVIMED entdecken
Crossref

Risks and uncertainties about gabapentinoids

Natalia Alzueta, Patricia García-González, Irati Irigoyen

Boletín de información farmacoterapéutica de Navarra · 2021

DOI: 10.54095/bitn20212902en ↗

Kurz gefasst

Fachartikel in der Zeitschrift Boletín de información farmacoterapéutica de Navarra, 2021. Verfasst von Natalia Alzueta und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The use of gabapentinoids has increased in the recent years. Approved indications include epilepsy, peripheral neuropathic pain, diabetic neuropathy, postherpetic neuralgia and anxiety disorder. However, these drugs are widely prescribed off-label for indications such as low back pain, fibromyalgia, migraine or restless legs syndrome. Side effects associated with these drugs are common, highlighting the risk of respiratory depression when combined with other drugs that depress the central nervous system, suicidal ideation, abuse and addiction. OBJETIVE To review the evidence available on the uses of gabapentinoids (epilepsy excluded) and its associated risks. METHODS A search in Tripdatabase and Dynamed was conducted for clinical practice guidelines. In addition, a PubMed search was performed including systematic reviews, clinical trials and observational studies in order to analyze the evidence available on these drugs for their different indications. Data about the use of gabapentinoids in Navarre were obtained from the electronic prescription database of the public health system of Navarre -Osasunbidea (SNS-O). CONCLUSIONS Off-label use of gabapentinoids is not recommended due to the lack of consistent evidence available and its potential risks (sedation, dizziness or respiratory depression). Some recommendations are provided for a safe prescription of gabapentinoids.

Zitieren

APA

Alzueta, N., García-González, P., & Irigoyen, I. (2021). Risks and uncertainties about gabapentinoids. Boletín de información farmacoterapéutica de Navarra. https://doi.org/10.54095/bitn20212902en

Vancouver

Alzueta N, García-González P, Irigoyen I. Risks and uncertainties about gabapentinoids. Boletín de información farmacoterapéutica de Navarra. 2021. doi:10.54095/bitn20212902en

BibTeX
@article{Alzueta2021,
  author = {Alzueta, Natalia and García-González, Patricia and Irigoyen, Irati},
  title = {Risks and uncertainties about gabapentinoids},
  journal = {Boletín de información farmacoterapéutica de Navarra},
  year = {2021},
  doi = {10.54095/bitn20212902en}
}
Kostenlos starten →